Clinical trials: Congestive Heart Failure Chronic
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the…
- Trial name
- OSICAT (NCT02068118)
- Testing
- Telecardiology program
- Where
- 38 sites in France, Martinique
- Volunteers
- 990 people
- Sponsor
- CDM e-Health
Cardiomyopathies, Heart Diseases
Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
Chronic viral cardiomyopathy is a disease where the cardiac muscle is attacked by a virus and this may result in a reduction in the output of the heart (pump function) thereby causing complaints such as chest pain, shortness of…
- Trial name
- NCT00185250
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
- Where
- 31 sites in France, Germany and 5 more
- Volunteers
- 138 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure (HF)
SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
The SchlaHF XT Registry is a longitudinal study of patients with heart failure (HF). The study aims to understand the importance of diagnosis and treatment of sleep disordered breathing (SDB) on HF with the following questions…
- Trial name
- NCT02301689
- Where
- Germany
- Volunteers
- 4,749 people
- Sponsor
- ResMed
Chronic Heart Failure
R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances
To determine the usability and technical aspects of Cordio HearO™
- Trial name
- NCT05876533
- Testing
- Cordio HearO
- Where
- 8 sites in United States, Israel
- Volunteers
- 216 people
- Sponsor
- Cordio Medical
Heart Failure
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
This trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood…
- Trial name
- NCT07687186
- Testing
- Qishen Yiqi Dripping Pills 2 bags
- Where
- 60 sites in China
- Volunteers
- 636 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure, Heart Failure Preserved Ejection Fraction
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-2-PEF (NCT06215586)
- Testing
- Tovinontrine (CRD-750)
- Where
- 84 sites in United States, Australia and 13 more
- Volunteers
- 303 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Chronic Heart Failure
Effect of Enhanced Sweat Rate on the Safety and Edema Status of Chronic Edematous Patients
The purpose of this study is to demonstrate safety and performance of AquaPass System for enhancing fluid transfer through the skin, by increased sweat rate, in edematous patients.
- Trial name
- NCT04578353
- Testing
- The AquaPass System
- Where
- Israel
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AquaPass Medical Ltd.
Chronic Heart Failure
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.
- Trial name
- NCT00272805
- Testing
- carvedilol
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- Cardiovascular Clinical Sciences Inc
Congestive Heart Failure, Chronic Heart Failure
Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS
This is a randomized, open-label, three-way crossover design study with 3 treatment groups:TREATMENT A: Furosemide;TREATMENT B: Nesiritide administered IV bolus, followed by an infusion for 6 hours;TREATMENT C: Treatment B for at…
- Trial name
- NCT00652652
- Testing
- nesiritide, furosemide
- Sponsor
- Scios, Inc.
Heart Failure
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic…
- Trial name
- NCT02329834
- Testing
- Fursemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- scPharmaceuticals, Inc.
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Cardiovascular Risk, Heart Failure
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease).
- Conditions
- Cardiovascular Risk, Heart Failure, Chronic Kidney Disease
- Trial name
- POSEIDON (NCT06122961)
- Testing
- No treatment given
- Where
- 195 sites in United States, Argentina and 15 more
- Volunteers
- 18,198 people
- Sponsor
- Novo Nordisk A/S
Chronic Heart Failure
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and <137 mmol/L).
- Trial name
- NCT00032747
- Testing
- Vasopressin V2 Receptor Antagonist
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 338 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
- Trial name
- NCT03388593
- Testing
- rhNRG-1
- Where
- 65 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Heart Failure
Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure
Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in patients with Chronic Heart Failure.
- Trial name
- NCT06348498
- Testing
- Jia Shen Tablet
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.